Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

Skin toxicity is the most common toxicity caused by Epidermal Growth Factor Receptor (EGFR) inhibitors, and has been associated with clinical efficacy. As EGFR inhibitors enhance the expression of antigen presenting molecules in affected skin keratinocytes, they may concurrently facilitate neo-antigen presentation in lung cancer tumor cells contributing to anti-tumor immunity. Here, we investigated the modulatory effect of the EGFR inhibitor, erlotinib on antigen presenting molecules and PD-L1, prominent immune checkpoint protein, of skin keratinocytes and lung cancer cell lines to delineate the link between EGFR signaling pathway inhibition and potential anti-tumor immunity. Erlotinib up-regulated MHC-I and MHC-II proteins on IFNγ treated keratinocytes but abrogated IFNγ-induced expression of PD-L1, suggesting the potential role of infiltrating autoreactive T cells in the damage of keratinocytes in affected skin. Interestingly, the surface expression of MHC-I, MHC-II, and PD-L1 was up-regulated in response to IFNγ more often in lung cancer cell lines sensitive to erlotinib, but only expression of PD-L1 was inhibited by erlotinib. Further, erlotinib significantly increased T cell mediated cytotoxicity on lung cancer cells. Lastly, the analysis of gene expression dataset of 186 lung cancer cell lines from Cancer Cell Line Encyclopedia demonstrated that overexpression of PD-L1 was associated with sensitivity to erlotinib and higher expression of genes related to antigen presenting pathways and IFNγ signaling pathway. Our findings suggest that the EGFR inhibitors can facilitate anti-tumor adaptive immune responses by breaking tolerance especially in EGFR driven lung cancer that are associated with overexpression of PD-L1 and genes related to antigen presentation and inflammation.

[1]  G-H Sun,et al.  CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer , 2016, Oncogene.

[2]  Jia-Nan Cheng,et al.  EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. , 2015, Biochemical and biophysical research communications.

[3]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Huang,et al.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  D. Ettinger,et al.  Non-Small Cell Lung Cancer, Version 6.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  David C. Smith,et al.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[8]  Ge Li,et al.  The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs , 2015, Oncotarget.

[9]  N. Reguart,et al.  Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. , 2015, Future oncology.

[10]  J. Gershan,et al.  Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma , 2015, Journal of Immunotherapy for Cancer.

[11]  A. Chella,et al.  PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients , 2014, British Journal of Cancer.

[12]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[13]  N. Okiyama,et al.  Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. , 2014, Journal of autoimmunity.

[14]  V. Krajka-Kuźniak,et al.  The effect of resveratrol and its methylthio-derivatives on EGFR and Stat3 activation in human HaCaT and A431 cells , 2014, Molecular and Cellular Biochemistry.

[15]  Y. Nakanishi,et al.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Rüdiger,et al.  Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. , 2014, European journal of cancer.

[17]  Travis J Cohoon,et al.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, Cancer discovery.

[18]  E. Celis,et al.  EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy , 2013, British Journal of Cancer.

[19]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[20]  F. Bernard,et al.  Keratinocytes under Fire of Proinflammatory Cytokines: Bona Fide Innate Immune Cells Involved in the Physiopathology of Chronic Atopic Dermatitis and Psoriasis , 2012, Journal of allergy.

[21]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[22]  C. Drake Combination immunotherapy approaches. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Adam A. Margolin,et al.  22 The Cancer Cell Line Encyclopedia - Using Preclinical Models to Predict Anticancer Drug Sensitivity , 2012 .

[24]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[25]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[26]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[27]  A. Stevens,et al.  TNF-α and TGF-β Counter-Regulate PD-L1 Expression on Monocytes in Systemic Lupus Erythematosus , 2012, Scientific Reports.

[28]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .

[29]  T. Cartee,et al.  Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes , 2011, Clinical Cancer Research.

[30]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[31]  Jian Zhang,et al.  CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression , 2010, Cancer and Metastasis Reviews.

[32]  J. Verweij,et al.  Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. , 2010, European journal of cancer.

[33]  M. Azuma,et al.  Keratinocyte-Associated B7-H1 Directly Regulates Cutaneous Effector CD8+ T Cell Responses , 2010, The Journal of Immunology.

[34]  D. Threadgill,et al.  EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. , 2010, The Journal of investigative dermatology.

[35]  Clare L. Bennett,et al.  Keratinocytes function as accessory cells for presentation of endogenous antigen expressed in the epidermis. , 2009, The Journal of investigative dermatology.

[36]  R. Perez-soler,et al.  Skin toxicities associated with epidermal growth factor receptor inhibitors , 2009, Targeted Oncology.

[37]  Giampiero Girolomoni,et al.  The epidermal growth factor receptor system in skin repair and inflammation. , 2008, The Journal of investigative dermatology.

[38]  Gary Clark,et al.  Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies , 2007, Clinical Cancer Research.

[39]  F. Di Virgilio,et al.  Stimulation of purinergic receptors modulates chemokine expression in human keratinocytes. , 2007, The Journal of investigative dermatology.

[40]  G. Besra,et al.  Expression of CD1d Molecules by Human Schwann Cells and Potential Interactions with Immunoregulatory Invariant NK T Cells1 , 2006, The Journal of Immunology.

[41]  L. Seymour,et al.  Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. , 2006, Clinical lung cancer.

[42]  S. Aractingi,et al.  Cetuximab-Induced Acne , 2005, Dermatology.

[43]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[44]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[45]  K. Omura,et al.  The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. , 2004, Immunology letters.

[46]  U. Rodeck,et al.  Complex Regulation of Signal Transducers and Activators of Transcription 3 Activation in Normal and Malignant Keratinocytes , 2004, Cancer Research.

[47]  G. Girolomoni,et al.  Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. , 2003, The American journal of pathology.

[48]  T. Luger,et al.  Keratinocytes in epidermal immune responses , 2001, Current opinion in allergy and clinical immunology.

[49]  F. Khuri,et al.  Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[51]  J. Kolesar,et al.  Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). , 2014, European journal of cancer.

[52]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[53]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.